Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.
The global gout disease treatment market was valued atUS$ 2,385.7million in 2018, and is expected to exhibit a CAGR of6.7%during the forecast period (2019–2027).
Ask for the Sample of the Study:
Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.
Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.
Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.
Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.
Request PDF Brochure:
Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.
Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.
Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,
Browse the Full Report at
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/